Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 2/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.38 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20186451 | 0.81 | LPL (0.43) | LPLLIPGKMT2ASMN1; SMN2MAPT | |
| SCHEMBL20202145 | 0.78 | — | — | |
| SCHEMBL18000478 | 0.78 | MAPT (0.49) | LPLLIPGKMT2ASMN1; SMN2MAPT | |
| SCHEMBL23087468 | 0.72 | LPL (0.46) | LPLLIPGKMT2ADGAT1IRAK4 | |
| SCHEMBL1693694 | 0.72 | SMPD3 (0.46) | SMN1; SMN2MAPTLMNANPC1RAB9A | |
| SCHEMBL15286421 | 0.71 | CAMKK1 (0.56) | PIK3CDCAMKK1CAMKK2PIK3R1KMT2A | |
| SCHEMBL1356211 | 0.71 | DRD3 (0.40) | LPLLIPGKMT2ASMN1; SMN2MAPT | |
| SCHEMBL17856778 | 0.71 | LPL (0.47) | LPLLIPGKMT2ASMN1; SMN2MAPT | |
| SCHEMBL22923448 | 0.69 | FFAR1 (0.32) | — | |
| SCHEMBL9941911 | 0.68 | SCN5A (0.50) | LPLLIPGPIK3CDSCN5ADGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3548495-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3548495-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | GILEAD SCIENCES, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| WO-2018102384-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| WO-2018102384-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | GILEAD SCIENCES, INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10100058-B2 | Fused heterocyclic compounds as CaM kinase inhibitors | CAMK1, CAMKK1, CAMK1D | LPL 4165/4885LIPG 3835/4885PIK3CD 297/4885 |
| US-20180148457-A1 | FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS | CAMK1, CAMKK1, CAMK1D | LPL 4165/4885LIPG 3835/4885PIK3CD 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.